References
- Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.
- Colao A. The prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:575–596.
- Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16:545–553.
- Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8:3–6.
- Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an international pituitary pathology club proposal. Endocr Relat Cancer. Internet]. 2017 [cited 2019 Jan 21];24:C5–C8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28264912
- Heaney AP. Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96:3649–3660.
- Abbara A, Clarke SA, Nesbitt A, et al. Interpretation of serum gonadotropin levels in hyperprolactinaemia. Neuroendocrinology. Internet]. 2018 [cited 2019 Jan 7];107:105–113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29660734
- Page-Wilson G, Smith PC, Welt CK. prolactin suppresses GnRH but not TSH secretion. Horm Res Paediatr. Internet]. 2006 [cited 2019 Jan 7];65:31–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16357488
- Sonigo C, Bouilly J, Carré N, et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. Internet]. 2012 [cited 2019 Jan 7];122:3791–3795. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23006326
- Kaiser UB. Hyperprolactinemia and infertility: new insights. J Clin Invest. Internet]. 2012 [cited 2019 Jan 7];122:3467–3468. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23193578
- Comninos AN, Demetriou L, Wall MB, et al. Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions. JCI Insight. Internet]. 2018 [cited 2019 Jan 7];3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30333302
- Mazziotti G, Porcelli T, Mormando M, et al. Vertebral fractures in males with prolactinoma. Endocrine. Internet]. 2011 [cited 2019 Jan 21];39:288–293. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21479837
- Mazziotti G, Mancini T, Mormando M, et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. Internet]. 2011 [cited 2019 Jan 21];14:299–306. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21301967
- Tirosh A, Benbassat C, Lifshitz A, et al. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary. 2015;18:108–115.
- Molitch ME. Diagnosis and treatment of pituitary adenomas. JAMA. 2017;317:516.
- Tirosh A, Shimon I. Management of macroprolactinomas. Clin Diabetes Endocrinol. 2015;1:5.
- Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724–763.
- Cuny T, Barlier A, Feelders R, et al. Medical therapies in pituitary adenomas: current rationale for the use and future perspectives. Ann Endocrinol (Paris). 2015;76:76.
- Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. Internet]. 1985 [cited 2018 Nov 4];60:698–705. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-60-4-698
- Dallabonzana D, Liuzzi A, Oppizzi G, et al. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J Clin Endocrinol Metab. 1986;63:1002–1007.
- Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol. 2011;7:267–278.
- Wong A, Eloy JA, Couldwell WT, et al. Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci. 2015;22:1568–1574.
- Kissner DG, Jarrett JC. Side effects of bromocriptine. N Engl J Med. Internet]. [cited 2018 Nov 4];302:749–750. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM198003273021313
- Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. Internet]. 2015 [cited 2018 Nov 4];172:R205–R213. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25805896
- Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. cabergoline comparative study group. N Engl J Med. 1994;331:904–909.
- Colao A, Di Sarno A, Guerra E, et al. Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab. 2006;2:200–210.
- Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518–2522.
- Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89:1704–1711.
- Colao A, Di Sarno A, Landi ML, et al. macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. Internet]. 2000 [cited 2018 Sep 4];85:2247–2252. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10852458
- Delgrange E, Daems T, Verhelst J, et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747–752.
- Delgrange E, Raverot G, Bex M, et al. Giant prolactinomas in women. Eur J Endocrinol. Internet]. 2014;170:31–38. Available from: https://eje.bioscientifica.com/view/journals/eje/170/1/31.xml
- Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100:1177–1186.
- Raverot G, Jacob M, Jouanneau E, et al. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol (Oxf). Internet]. 2009 [cited 2019 Jan 7];70:588–592. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18673461
- Netea-Maier RT, van Lindert EJ, Timmers H, et al. Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas. J Endocrinol Invest. Internet]. 2006 [cited 2018 Nov 4];29:1001–1005. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17259798
- Paepegaey A-C, Salenave S, Kamenicky P, et al. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J Endocr Soc. 2017;1:221–230.
- Vroonen L, Lancellotti P, Garcia MT, et al. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine. 2017;55:239–245.
- Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. Internet]. 2011 [cited 2018 Nov 5];96:273–288. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21296991
- Noronha S, Stokes V, Karavitaki N, et al. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine. 2016;51:205–210.
- Van’t Verlaat JW, Croughs RJ, Brownell J. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205–502. Clin Endocrinol (Oxf). Internet]. 1990 [cited 2019 Jan 21];33:619–624. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1979262
- Kvistborg A, Halse J, Bakke S, et al. Long-term treatment of macroprolactinomas with CV 205–502. Acta Endocrinol (Copenh). Internet]. [cited 2019 Jan 21];128:301–307. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8098891
- Schultz PN, Ginsberg L, McCutcheon IE, et al. Quinagolide in the management of prolactinoma. Pituitary. 2000;3:239–249.
- Di Sarno A, Landi ML, Marzullo P, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf). 2000;53:53–60.
- Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29–38.
- Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46.
- Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. Internet]. 2014 [cited 2018 Nov 4];117:421–428. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24146188
- Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. Internet]. 2008 [cited 2018 Nov 5];93:4721–4727. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2007-2758
- Vroonen L, Jaffrain-Rea M-L, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167:651–662.
- Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989;69:500–509.
- Pellegrini I, Costa R, Grisoli F, et al. Abnormal dopamine sensitivity in some human prolactinomas. Horm Res. 1989;31:19–23.
- Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 1994;60:314–322.
- Caccavelli L, Morange-Ramos I, Kordon C, et al. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol. 1996;8:737–746.
- Shimazu S, Shimatsu A, Yamada S, et al. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. Eur J Endocrinol. 2012;166:383–390.
- Bueno C, Trarbach E, Bronstein M, et al. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment. Pituitary. 2017;20:295–300.
- Filopanti M, Barbieri AM, Angioni AR, et al. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J. 2008;8:357–363.
- Gao H, Wang F, Lan X, et al. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer. 2015;15:15.
- Cheedipudi S, Puri D, Saleh A, et al. A fine balance: epigenetic control of cellular quiescence by the tumor suppressor PRDM2/RIZ at a bivalent domain in the cyclin a gene. Nucleic Acids Res. Internet]. 2015 [cited 2018 Nov 4];43:6236–6256. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26040698
- Recouvreux MV, Camilletti MA, Rifkin DB, et al. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas. J Endocrinol. 2016;228:R73–R83.
- Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–791.
- Heldin C-H, Miyazono K, Ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465–471.
- Sarkar DK, Kim KH, Minami S. Transforming growth factor-beta 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol. 1992;6:1825–1833.
- Recouvreux MV, Guida MC, Rifkin DB, et al. Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary. Endocrinology. 2011;152:2722–2730.
- Li Z, Liu Q, Li C, et al. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas. Mol Cell Endocrinol. 2015;402:64–71.
- Marini F, Falchetti A, Monte F, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis. Internet]. 2006 [cited 2018 Nov 5];1:38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17014705
- Vergès B, Boureille F, Goudet P, et al. Pituitary disease in men type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87:457–465.
- Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): A case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32:534–543.
- Delemer B. MEN1 and pituitary adenomas. Ann Endocrinol (Paris). 2012;73:59–61.
- Subasinghe CJ, Somasundaram N, Sivatharshya P, et al. Giant prolactinoma of young onset: a clue to diagnosis of MEN-1 syndrome. Case Rep Endocrinol. Internet]. 2018 [cited 2018 Nov 4];2018:1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30186640
- Beckers A, Aaltonen LA, Daly AF, et al. familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. Internet]. 2013 [cited 2018 Nov 21];34:239–277. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23371967
- Peverelli E, Mantovani G, Vitali E, et al. Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab. 2012;97:967–977.
- Wang F, Gao H, Li C, et al. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. J Neurooncol. 2014;116:83–88.
- Huang HY, Zhai W, Tang H, et al. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas. Endocrine. Internet]. 2018 [cited 2019 Jan 20];62:464–469. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30238326
- Dos Santos Nunes V, El Dib R, Boguszewski CL, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. Internet]. 2011 [cited 2018 Nov 4];14:259–265. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21221817
- Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol. Internet]. 1996 [cited 2019 Jan 20];134:454–456. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8640297
- Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. Internet]. 1997 [cited 2019 Jan 21];82:876–883. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9062500
- Gillam MP, Middler S, Freed DJ, et al. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab. Internet]. [cited 2019 Jan 20];87:4447–4451. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2002-020426
- Iyer P, Molitch M. positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Endocr Pract. Internet]. 2011 [cited 2019 Jan 20];17:e55–e58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21324816
- Kreutzer J, Buslei R, Wallaschofski H, et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008;158:11–18.
- Shimon I, Sosa E, Mendoza V, et al. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary. 2016;19:429–436. Internet]. Available from: http://link.springer.com/10.1007/s11102-016-0723-4
- Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. Internet]. 2007 [cited 2019 Jan 7];156:225–231. Available from: https://eje.bioscientifica.com/view/journals/eje/156/2/1560225.xml
- Corsello SM, Ubertini G, Altomare M, et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003;58:662–670.
- Hamilton DK, Vance ML, Boulos PT, et al. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2005;8:53–60.
- Dallapiazza RF, Jane JA. Outcomes of endoscopic transsphenoidal pituitary surgery. Endocrinol Metab Clin North Am. 2015;44:105–115.
- Jan M, Dufour H, Brue T, et al. Prolactinoma surgery. Ann Endocrinol (Paris). 2007;68:118–119.
- Song Y-J, Chen M-T, Lian W, et al. Surgical treatment for male prolactinoma. Medicine (Baltimore). 2017;96:e5833.
- Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012;166:779–786.
- Donegan D, Atkinson JLD, Jentoft M, et al. Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract. 2017;23:37–45.
- Castinetti F, Régis J, Dufour H, et al. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol. 2010;6:214–223.
- Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009;94:3400–3407.
- Pouratian N, Sheehan J, Jagannathan J, et al. gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery. 2006;59:255–266.
- Ježková J, Hána V, Kršek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf). 2009;70:732–741.
- Tanaka S, Link MJ, Brown PD, et al. gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg. Internet]. 2010 [cited 2019 Jan 8];74:147–152. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1878875010002020
- Cohen-Inbar O, Xu Z, Schlesinger D, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary. 2015;18:820–830.
- Castinetti F, Brue T. Gamma knife radiosurgery in pituitary adenomas: why, who, and how to treat? Discov Med. 2010;10:107–111.
- Regis J, Castinetti F. Radiosurgery: a useful first-line treatment of prolactinomas? World Neurosurg. 2010;74:103–104.
- Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. Internet]. 2005 [cited 2018 Nov 6];352:987–996. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15758009
- Zhang J, Stevens MFG, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. Internet]. [cited 2019 Jan 22];5:102–114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22122467
- Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. Internet]. 2005 [cited 2019 Jan 16];352:997–1003. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15758010
- Lim S, Shahinian H, Maya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7:518–520.
- Raverot G, Sturm N, De Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A French multicenter experience. J Clin Endocrinol Metab. 2010.
- Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012;76:769–775.
- Lasolle H, Cortet C, Castinetti F, et al. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol. 2017;176:769–777.
- Philippon M, Morange I, Barrie M, et al. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Ann Endocrinol (Paris). Internet]. 2012 [cited 2018 Nov 7];73:225–229. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22520146
- Raverot G, Burman P, McCormack A, et al. European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1–G24.
- Fusco A, Gunz G, Jaquet P, et al. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol. 2008;158:595–603.
- Fusco A, Lugli F, Sacco E, et al. Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary. 2011;14:351–357.
- Sosa-Eroza E, Espinosa E, Ramírez-Rentería C, et al. Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR. Endocrine. Internet]. 2018 [cited 2018 Nov 4];61:343–348. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29948930
- Cuny T, Mohamed A, Graillon T, et al. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion. Mol Cell Endocrinol. 2012;355:106–113.
- Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875–884.
- Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89:1577–1585.
- Fedele M, De Martino I, Pivonello R, et al. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin Cancer Res. 2007;13:2738–2744.
- Lasolle H, Vasiljevic A, Borson-Chazot F, et al. Pasireotide: a potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris). Internet]. 2018 [cited 2018 Nov 1]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30318256
- Baldari S, Ferraù F, Alafaci C, et al. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary. Internet]. 2012 [cited 2018 Nov 9];15 Suppl 1: S57–60. Available from: http://link.springer.com/10.1007/s11102-011-0373-5
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. Internet]. 2017 [cited 2018 Jul 14];376:125–135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28076709
- Liu X, Liu Y, Gao J, et al. Combination treatment with bromocriptine and metformin in patients with bromocriptine-resistant prolactinomas: pilot study. World Neurosurg. 2018;115:94–98.
- Gao J, Liu Y, Han G, et al. Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts. J Cell Mol Med. Internet]. 2018 [cited 2018 Nov 4]; 22:6368–6379. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30334324
- Esparís-Ogando A, Montero JC, Arribas J, et al. Targeting the EGF/HER ligand-receptor system in cancer. Curr Pharm Des. Internet]. 2016 [cited 2018 Nov 6];22:5887–5898. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27426127
- Kontogeorgos G, Stefaneanu L, Kovacs K, et al. Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: an immunocytochemical study. Endocr Pathol. 1996;7:63–70.
- Cooper O, Mamelak A, Bannykh S, et al. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine. 2014;46:318–327.
- Cooper O, Vlotides G, Fukuoka H, et al. Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer. 2011;18:R197–R211.
- Vlotides G, Siegel E, Donangelo I, et al. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 2008;68:6377–6386.
- Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976.
- Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer. 2009;16:1329–1338.
- Roof AK, Jirawatnotai S, Trudeau T, et al. The balance of PI3K and ERK signaling is dysregulated in prolactinoma and modulated by dopamine. Endocrinology. 2018;159:2421–2434.
- Chen R, Duan J, Li L, et al. MTOR promotes pituitary tumor development through activation of PTTG1. Oncogene. 2017;36:979.
- Geng X, Ma L, Li Z, et al. Bromocriptine induces autophagy-dependent cell death in pituitary adenomas. World Neurosurg. 2017;100:407–416.
- Zhang D, Way JS, Zhang X, et al. Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab. Internet]. 2019 [cited 2019 Jan 20]; Available from: https://academic.oup.com/jcem/advance-article/doi/10.1210/jc.2018-02461/5273783
- Smith TR, Hulou MM, Huang KT, et al. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci. Internet]. 2015 [cited 2018 Nov 4];22:1785–1791. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26277642
- Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015;3:906–913.
- Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. Internet]. 2013 [cited 2019 Mar 9];126:123–135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23400299
- Eroukhmanoff J, Tejedor I, Potorac I, et al. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur J Endocrinol. 2017;176:123–132.
- Lin AL, Jonsson P, Tabar V, et al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab. Internet]. 2018 [cited 2019 Jan 23];103:3925–3930. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30085142
- Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574–3579.
- Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf). 1997;46:409–413.
- Espinosa E, Sosa E, Mendoza V, et al. Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine. 2016;52:652–659.
- Green AI, Sherlock M, Stewart PM, et al. Extensive experience in the management of macroprolactinomas. Clin Endocrinol (Oxf). 2014;81:85–92.
- Wu ZR, Zhang Y, Cai L, et al. Long-term clinical outcomes of invasive giant prolactinomas after a mean ten-year followup. Int J Endocrinol. 2016;2016:1–7.
- Rohmer V, Freneau E, Morange I, et al. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. club de l’Hypophyse. Ann d Endocrinol. 2000;61:411–417.